COPPELL, Texas--(BUSINESS WIRE)--Mannatech®, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced the appointment of David Ori, a direct sales industry veteran, to the position of Vice President of EMEA. In this position, Ori will be responsible for expanding the company’s European, Middle East and African markets, strengthening international business efforts and supporting Mannatech’s independent sales Associates in this region.
Ori’s hiring is in line with Mannatech’s strategy for building and strengthening its global leadership as it continues to expand its international operations and align its foreign markets with cohesive direction, purpose and ambitious objectives.
“David’s experience in the direct sales industry and international markets will help us create effective strategies for rapid global expansion while providing unique insights into addressing Associate needs,” said Alfredo “Al” Bala, Mannatech’s CEO and President. “He will be instrumental in helping us lead and grow our operations in those regions, and his valuable work experience will enable us to better serve our Associates.”
Ori joins Mannatech with more than 20 years of experience within the direct selling industry as well as international market expertise. Prior to joining Mannatech, Ori served as vice president of international development for Youngevity International, where he was responsible for leading the global expansion team, building international infrastructure and managing a global team in several regions.
He has also held several other positions including vice president of international expansion and general manager of China, Hong Kong and Taiwan for Isagenix International. Ori has worked for other direct selling companies including Nikken and Tupperware. He earned a bachelor’s degree in business administration from Suffolk University, and in addition to English, he speaks Hebrew and Arabic.
To begin transforming your life or the lives of those around you, please visit Mannatech.com.
Mannatech, Incorporated, offers a profound wellness experience through a financially rewarding opportunity that makes a difference in the lives of people across the world. Through its innovative glyconutrition products*, Mannatech transforms lives, providing an unprecedented level of natural wellness, freedom and purpose.* With more than 20 years of experience and operations in more than 25 countries, Mannatech is committed to transforming lives. For more information, visit Mannatech.com.
Please note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.
* These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.